#LetsBeBlunt #MontelWilliams #Terpenes

Most cannabis conversations focus on how the plant is grown.

Almost no one talks about what happens after.

In this episode of Let’s Be Blunt with Montel, Montel sits down with inventor and engineer David Sandelman, co-founder of Cannatrol, to break down the most overlooked — and arguably most critical — stage in cannabis: post-harvest processing.

Drying and curing determine everything.

Flavor. Potency. Safety. Consistency.

Yet much of the industry still relies on outdated techniques passed down from the illicit market — methods that can destroy terpene profiles, reduce therapeutic value, and increase the risk of mold contamination.

Sandelman, a serial inventor with 19 patents and decades of experience in environmental control systems, is changing that. Through Cannatrol’s patented technology, he’s bringing precision, repeatability, and science into a part of cannabis that has long operated on guesswork.

This conversation goes beyond cultivation — into the chemistry, physics, and responsibility behind delivering safe, high-quality cannabis to both adult-use consumers and medical patients.

Because cannabis isn’t just grown.

It’s finished.

And how it’s finished… changes everything.

• Why drying and curing may be the most important step in cannabis production
• How terpene preservation directly impacts experience and therapeutic effect
• The real risks of mold and improper post-harvest handling
• Why traditional curing methods often fall short in a regulated market
• How science and environmental control are reshaping cannabis quality standards
• What the future of cannabis looks like as it evolves into a precision-driven industry

The difference between average cannabis and exceptional cannabis isn’t just how it’s grown — it’s how it’s finished.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Let’s Be Blunt with Montel, Montel sits down with pediatric pharmacist, clinical researcher, and patient-rights advocate Codi Peterson to explore one of the most discussed — and often misunderstood — topics in cannabis science: Cannabinoid Hyperemesis Syndrome (CHS).

Codi brings a unique perspective to the conversation, bridging clinical healthcare, public policy, and cannabis research. As a board member of Americans for Safe Access, Codi has been deeply involved in the fight for federal cannabis reform, patient access, and evidence-based cannabis education.

The discussion dives into Codi’s upcoming clinical research study surveying more than 1,100 individuals experiencing symptoms consistent with CHS, offering new insight into this emerging condition and how it is being interpreted in medicine and media.

Montel and Codi break down what CHS actually is, why it occurs in some individuals but not others, and how the lack of federal cannabis research has contributed to confusion, stigma, and misinformation around the topic.

The episode also explores the broader issues surrounding cannabis patient rights, physician education, harm-reduction strategies, and the future of cannabis medicine in the United States.

This is a thoughtful and science-driven conversation about how we can move beyond fear and misinformation toward responsible cannabis education and patient safety.

In This Episode

• What Cannabinoid Hyperemesis Syndrome (CHS) really is

• Why some heavy cannabis users experience cyclical vomiting

• What new research from a 1,100-person CHS survey reveals

• Why federal cannabis prohibition still blocks medical research

• The role of patient rights and advocacy in cannabis policy

• How physicians and pharmacists should approach cannabis education

• Why responsible cannabis use requires better public health information

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Migraine is not just a headache — it’s one of the most disabling neurological conditions in the world. It steals time, productivity, and quality of life from millions of people. And despite decades of pharmaceutical innovation, far too many patients are still left searching for real relief.

In this episode of Let’s Be Blunt with Montel, I sit down with one of the most respected neurologists in the country, Dr. Laszlo Mechtler — President and Medical Director of the DENT Neurologic Institute — to unpack what’s really happening in migraine care today… and where it’s headed next.

Dr. Mechtler has treated tens of thousands of neurological patients, including more than 15,000 within his cannabis-focused clinic. What he’s seen firsthand is something many patients already know: the current system often relies on trial-and-error, cycling through medications that don’t always work — and sometimes come with significant side effects.

So the question becomes:
What if we could move beyond guesswork?

We explore how cannabinoid-based therapies are being integrated into modern neurology — not as a replacement for traditional medicine, but as part of a more personalized, patient-centered approach. From reducing migraine frequency to improving sleep and quality of life, Dr. Mechtler shares what the data — and his clinical experience — are beginning to reveal.

But this conversation goes even deeper.

Dr. Mechtler is now partnering with Cannformatics on a groundbreaking initiative to develop Cannabis-Responsive biomarkers — a data- and AI-driven approach designed to predict which patients are most likely to benefit from cannabinoid therapy.

In simple terms:
Instead of “try this and see,” we’re asking, “Does your biology suggest this will work for you?”

We break down:

• Why so many migraine patients remain underserved
• What clinicians are seeing in real-world cannabis use
• How biomarkers could transform cannabis into precision medicine
• The upcoming 150-patient research study — and why it starts with responders
• What this means for the future of neurology, research, and patient care

This is where the conversation shifts — from stigma to science, from anecdote to evidence.

For patients who feel dismissed…
For clinicians searching for better tools…
And for anyone interested in the future of medicine — this is a conversation you don’t want to miss.

Because this isn’t about replacing medicine.
It’s about improving it.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.